Gastrointestinal Diagnostics Market Size, Share and Growth Outlook, 2026

Gastrointestinal Diagnostics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Gastrointestinal Diagnostics Market size is forecast to increase from $5.97 Billion in 2026 to $8.28 Billion in 2034 at a CAGR of 4.18% between 2026 and 2034.

The Gastrointestinal Diagnostics market report provides detailed analysis and outlook of Gastrointestinal Diagnostics segments including By Test Type (Endoscopy, Blood Tests, Stool-based Tests, Breath Tests, Biopsy & Imaging), By Technology (Polymerase Chain Reaction, Enzyme-Linked Immunosorbent Assay, Rapid Diagnostic Tests, Culture and Sensitivity Testing), By Application (Gastrointestinal Infections, Gastrointestinal Cancer, Inflammatory Bowel Disease, Gastroesophageal Reflux Disease ), By Test Location (Central Laboratories, Point-of-Care) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Gastrointestinal Diagnostics Industry Overview

High-Throughput Multiplex PCR Systems Enhancing Rapid GI Pathogen Detection

The Gastrointestinal Diagnostics Industry is advancing through automated, high-throughput molecular testing platforms designed to improve pathogen detection speed and diagnostic accuracy. QIAGEN N.V. has received FDA 510(k) clearance for its QIAstat-Dx® Gastrointestinal Panels on the QIAstat-Dx Rise system, enabling laboratories to process up to 160 tests per day. The platform uses multiplex real-time PCR technology to detect bacterial, viral, and parasitic pathogens responsible for gastrointestinal infections, delivering results in approximately one hour with minimal manual intervention. This automation significantly enhances laboratory efficiency while improving turnaround time for acute infectious disease diagnosis.

Ingestible Capsule Diagnostics Transforming Non-Invasive Gastrointestinal Monitoring

The Gastrointestinal Diagnostics Industry is increasingly adopting ingestible sensor technologies that enable real-time physiological monitoring of digestive tract conditions. Atmo Biosciences has expanded its U.S. operations following FDA 510(k) clearance for its gas-sensing capsule platform, which measures oxygen, hydrogen, and carbon dioxide levels throughout the gastrointestinal tract. This technology provides continuous, non-invasive insights into gut function, offering an alternative to traditional motility and transit-time testing methods. By enabling localized physiological mapping, ingestible capsules are redefining diagnostic approaches for functional gastrointestinal disorders.

Standardized Sample Preparation Systems Improving Molecular Diagnostic Accuracy

The Gastrointestinal Diagnostics Industry is also advancing through innovations in sample collection and stabilization systems that enhance molecular testing reliability. The FDA has approved expanded use of FecalSwab® systems for standardized specimen processing across automated GI diagnostic platforms. These systems convert stool samples into stabilized liquid transport media, preserving nucleic acid integrity during transport and reducing degradation risks. This standardization improves laboratory workflow efficiency and ensures consistent diagnostic accuracy across molecular gastrointestinal testing pipelines, supporting broader adoption of automated infectious disease screening technologies.

Gastrointestinal Diagnostics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Gastrointestinal Diagnostics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers, Thermo Fisher Scientific, bioMérieux, Danaher Corporation (Beckman Coulter), Bio-Rad Laboratories, Quest Diagnostics, Meridian Bioscience, QuidelOrtho Corporation. The Gastrointestinal Diagnostics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Gastrointestinal Diagnostics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Gastrointestinal Diagnostics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Gastrointestinal Diagnostics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Gastrointestinal Diagnostics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Gastrointestinal Diagnostics Market Competitive Benchmarking and Company Analysis

Leading companies in Gastrointestinal Diagnostics industry include- Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers, Thermo Fisher Scientific, bioMérieux, Danaher Corporation (Beckman Coulter), Bio-Rad Laboratories, Quest Diagnostics, Meridian Bioscience, QuidelOrtho Corporation. The Gastrointestinal Diagnostics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Gastrointestinal Diagnostics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Gastrointestinal Diagnostics market remains one of the strongest-performing segments in the country.
The US Gastrointestinal Diagnostics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Gastrointestinal Diagnostics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Gastrointestinal Diagnostics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Gastrointestinal Diagnostics markets

Canada's strong Gastrointestinal Diagnostics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Gastrointestinal Diagnostics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Gastrointestinal Diagnostics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Gastrointestinal Diagnostics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Gastrointestinal Diagnostics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Gastrointestinal Diagnostics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Gastrointestinal Diagnostics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Gastrointestinal Diagnostics sales through 2034

France Gastrointestinal Diagnostics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Gastrointestinal Diagnostics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Gastrointestinal Diagnostics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Gastrointestinal Diagnostics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Gastrointestinal Diagnostics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Gastrointestinal Diagnostics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Gastrointestinal Diagnostics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Gastrointestinal Diagnostics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Gastrointestinal Diagnostics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Gastrointestinal Diagnostics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Gastrointestinal Diagnostics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Gastrointestinal Diagnostics Market Segmentation

By Test Type
Endoscopy
Blood Tests
Stool-based Tests
Breath Tests
Biopsy & Imaging
By Technology
Polymerase Chain Reaction
Enzyme-Linked Immunosorbent Assay
Rapid Diagnostic Tests
Culture and Sensitivity Testing
By Application
Gastrointestinal Infections
Gastrointestinal Cancer
Inflammatory Bowel Disease
Gastroesophageal Reflux Disease
By Test Location
Central Laboratories
Point-of-Care

Top Companies in Gastrointestinal Diagnostics Industry

Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Siemens Healthineers
Thermo Fisher Scientific
bioMérieux
Danaher Corporation (Beckman Coulter)
Bio-Rad Laboratories
Quest Diagnostics
Meridian Bioscience
QuidelOrtho Corporation

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025